The latest price target for Cullinan Therapeutics (NASDAQ:CGEM) was reported by Wedbush on September 18, 2024. The analyst firm set a price target for $36.00 expecting CGEM to rise to within 12 months (a possible 98.35% upside). 16 analyst firms have reported ratings in the last year.

The latest analyst rating for Cullinan Therapeutics (NASDAQ:CGEM) was provided by Wedbush, and Cullinan Therapeutics reiterated their outperform rating.

There is no last upgrade for Cullinan Therapeutics

There is no last downgrade for Cullinan Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cullinan Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cullinan Therapeutics was filed on September 18, 2024 so you should expect the next rating to be made available sometime around September 18, 2025.

While ratings are subjective and will change, the latest Cullinan Therapeutics (CGEM) rating was a reiterated with a price target of $36.00 to $36.00. The current price Cullinan Therapeutics (CGEM) is trading at is $18.15, which is out of the analyst’s predicted range.